Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aponermin Bridging for CAR-T in Extramedullary MM
NCT06793475Phase 2Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Apr 2025
- Primary completion
- Jun 2026
- Modality
- Cytokines & Interferons, Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of aponermin in multiple myeloma (MM), sponsored by Institute of Hematology and Blood Diseases Hospital. Started Apr 2025; status: recruiting.
02
Drugs
aponermin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06793475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06793475.